Summary
In order to evaluate the preventive efficacy, safety and usefulness of mesna (Sodium 2-mercaptoethane sulfonate) against ifosfamide-induced urinary disorders, a placebo-controlled double-blind comparative study was performed. Ifosfamide was administered by intravenous drip infusion at a daily dose of 2 g/m2 for 5 consecutive days, and mesna was intravenously administered at 20% of the ifosfamide dose, three times daily for 5 consecutive days. The results obtained are as follows. (a) Of 101 accrued patients, 91 patients were evaluated consisting of 45 for the mesna group and 46 for the placebo group. There was no intergroup difference in the number of the evaluated cases and patient characteristics. (b) Micturition pain and feeling of residual urine graded as moderate or severe were not observed for the mesna group, but were observed for the placebo group with incidences of 19.6% (9/46) for micturition pain and 15.2% (7/46) for feeling of residual urine; the intergroup differences in the appearance of these urinary symptoms were statistically significant (P=0.0003 for micturition pain;P=0.0009 for feeling of residual urine). The incidence of hematuria graded as moderate or severe was 6.7% (3/45) in the mesna group, which was significantly lower than the 32.6% (15/46) in the placebo group (P=0.0008). (c) No side-effect attributable to mesna was observed. (d) A judgment of “useful” was obtained in 80.0% (36/45) of the patients treated with mesna, which was significantly higher than the 34.8% (16/46) of the patients treated with placebo (P= near 0). On the basis of the above results, we conclude that the preventive efficacy, safety and usefulness of mesna against ifosfamide-induced urinary disorders have been well demonstrated in this study.
Similar content being viewed by others
References
Brade WP, Herdrich K, Varini M (1985) Ifosfamide — pharmacology, safety and therapeutic potential. Cancer Treat Rev 12:1–47
Brade WP, Herdrich K, Klein HO (1987) Ifosfamide — dosing and scheduling. Contrib Oncol 26:22–52
Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G (1979) Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneim Forsch 29:659–661
Brock N, Pohl J, Stekar J (1981) Studies on the urotoxicity of oxaza-phosphorine cytostatics and its prevention: 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds. Eur J Cancer Clin Oncol 17:1155–1163
Brock N, Pohl J, Stekar J, Scheef W (1982) Studies on the urutoxicity of oxazaphosphorine cytostatics and its prevenition: III. Profile of action of sodium 2-mercaptoethane sulfonate. Eur J Cancer Clin Oncol 18:1377–1387
Burkert H (1983) Clinical overview of mesna. Cancer Treat Rev 10 [Suppl A] 175–181
Creaven PJ, Allen LM, Cohen MH, Nelson RL (1976) Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724). Cancer Treat Rep 60:445–449
Hoefer-Janker H, Scheef W, Günther U, Hüls W (1975) Erfahrungen mit der fraktionierten Ifosfamide-Sto\therapie bei generalisierten malignen Tumoren. Med Welt 26:972–979
Manz I, Dietrich I, Przbylski M, Niemeyer U, Pohl J, Hilgard P, Brock N (1985) Identification and quantification of metabolite conjugates of activated cyclophosphamide and ifosfamide with mesna in urine by ion-pair extraction and fast atom bombardment mass spectrometry. Biomed Mass Spectrom 12:545–553
Scheef W, Soemer G (1981) The treatment of solid malignant tumors with Holoxan and Uromitexan. In: Burkert H, Nagel GA (eds) New experience with the oxazaphosphorines with special reference to the uroprotector Uromitexan — contributions to oncology. Karger, Basel, pp 21–24
Scheef W, Klein HO, Brock N, Burkert H, Günther U, HoeferJanker H, Mitrenga D, Schnitker J, Voigtmann R (1979) Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat Rep 63:501–505
Scheulen ME, Niederle N, Bremer K, Schütte J, Seeber S (1983) Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients. Cancer Treat Rev 10 [Suppl A] 93–101
Schnitker J, Brock N, Burkert H, Fichtner E (1976) Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide. Arzneim Forsch 26:1783–1783
Shaw IC, Graham MI (1987) Mesna — a short review. Cancer Treat Rev 14:67–86
World Health Organization (1979) WHO handbook for reporting results of cancer treatment, WHO, Geneva
Zalupski M, Baker LH (1988) Ifosfamide. J Natl Cancer Inst 80:556–566
Author information
Authors and Affiliations
Additional information
The contents of this study were reported at the 26th Annual Meeting of the Japan Society for Cancer Therapy (Niigata 1988) and the 16th International Congress of Chemotherapy (Jerusalem 1989)
Rights and permissions
About this article
Cite this article
Fukuoka, M., Negoro, S.i., Masuda, N. et al. Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol 117, 473–478 (1991). https://doi.org/10.1007/BF01612769
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01612769